Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33973930)
Watch
English
Raltegravir: The evidence of its therapeutic value in HIV-1 infection
scientific article published on June 15, 2010
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
review article
1 reference
stated in
Europe PubMed Central
title
Raltegravir: The evidence of its therapeutic value in HIV-1 infection
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
main subject
raltegravir
1 reference
based on heuristic
inferred from title
HIV type 1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
20694070
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20694070
retrieved
18 June 2024
Integrase inhibitor
1 reference
stated in
Europe PubMed Central
PubMed publication ID
20694070
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20694070
retrieved
18 June 2024
author
Nouri Neamati
series ordinal
2
object named as
Nouri Neamati
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
author name string
Kavya Ramkumar
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
language of work or name
English
0 references
publication date
15 June 2010
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
full work available at URL
https://www.dovepress.com/getfile.php?fileID=5034
file format
Portable Document Format
online access status
open access
1 reference
stated in
Europe PubMed Central
PubMed publication ID
20694070
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20694070
retrieved
18 June 2024
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20694070/?tool=EBI
file format
HTML
online access status
open access
content deliverer
PubMed Central
1 reference
stated in
Europe PubMed Central
PubMed publication ID
20694070
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20694070
retrieved
18 June 2024
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20694070/pdf/?tool=EBI
file format
Portable Document Format
online access status
open access
content deliverer
PubMed Central
1 reference
stated in
Europe PubMed Central
PubMed publication ID
20694070
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20694070
retrieved
18 June 2024
https://europepmc.org/articles/PMC2899791
file format
HTML
online access status
open access
content deliverer
Europe PubMed Central
1 reference
stated in
Europe PubMed Central
PubMed publication ID
20694070
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20694070
retrieved
18 June 2024
https://europepmc.org/articles/PMC2899791?pdf=render
file format
Portable Document Format
online access status
open access
content deliverer
Europe PubMed Central
1 reference
stated in
Europe PubMed Central
PubMed publication ID
20694070
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20694070
retrieved
18 June 2024
https://www.dovepress.com/getfile.php?fileID=5034
1 reference
stated in
Crossref
DOI
10.2147/CE.S6004
reference URL
https://api.crossref.org/works/10.2147/CE.S6004
retrieved
18 June 2024
published in
Core Evidence
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
volume
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
page(s)
131-147
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
copyright license
Creative Commons Attribution-NonCommercial 3.0 Unported
start time
1 July 2009
1 reference
stated in
April 2022 Public Data File from Crossref
copyright status
copyrighted
0 references
cites work
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Emerging pharmacology: inhibitors of human immunodeficiency virus integration
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Etravirine for the treatment of HIV infection.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Raltegravir with optimized background therapy for resistant HIV-1 infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Lack of a significant drug interaction between raltegravir and tenofovir.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Class-sparing regimens for initial treatment of HIV-1 infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Review: mixing new cocktails: drug interactions in antiretroviral regimens
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Adverse effects of antiretroviral therapy for HIV infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
5 July 2018
Effects of omeprazole on plasma levels of raltegravir
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Exacerbation of depression associated with starting raltegravir: a report of four cases
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Severe rhabdomyolysis associated with raltegravir use.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Raltegravir treatment response in an HIV-2 infected patient: a case report
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Atazanavir modestly increases plasma levels of raltegravir in healthy subjects
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
New York state recommendations for drug-drug interactions between HAART, medications used in substance use treatment, and recreational drugs--a summary
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Antiretroviral-drug resistance among patients recently infected with HIV.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
A Simple, Dynamic Measure of Antiretroviral Therapy Adherence Predicts Failure to Maintain HIV‐1 Suppression
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2899791
retrieved
29 October 2018
Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20694070
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Maraviroc, risks and benefits: a review of the clinical literature
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20694070
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20694070
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.2147/CE.S6004
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
PMC publication ID
2899791
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
PubMed publication ID
20694070
1 reference
stated in
Europe PubMed Central
PMC publication ID
2899791
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
